Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 4
2007 1
2008 2
2010 2
2011 1
2020 2
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Halwani AS, et al. Among authors: yakovich a. Leuk Lymphoma. 2022 Apr;63(4):821-833. doi: 10.1080/10428194.2021.2010057. Epub 2021 Dec 6. Leuk Lymphoma. 2022. PMID: 34865586 Clinical Trial.
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.
Chawla SP, Van Tine BA, Pollack SM, Ganjoo KN, Elias AD, Riedel RF, Attia S, Choy E, Okuno SH, Agulnik M, von Mehren M, Livingston MB, Keedy VL, Verschraegen CF, Philip T, Bohac GC, Yurasov S, Yakovich A, Lu H, Chen M, Maki RG. Chawla SP, et al. Among authors: yakovich a. J Clin Oncol. 2022 Apr 20;40(12):1291-1300. doi: 10.1200/JCO.20.03452. Epub 2021 Jul 14. J Clin Oncol. 2022. PMID: 34260265 Clinical Trial.
Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds.
Das U, Gul HI, Alcorn J, Shrivastav A, George T, Sharma RK, Nienaber KH, De Clercq E, Balzarini J, Kawase M, Kan N, Tanaka T, Tani S, Werbovetz KA, Yakovich AJ, Manavathu EK, Stables JP, Dimmock JR. Das U, et al. Among authors: yakovich aj. Eur J Med Chem. 2006 May;41(5):577-85. doi: 10.1016/j.ejmech.2005.12.014. Epub 2006 Apr 3. Eur J Med Chem. 2006. PMID: 16581158
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. Somaiah N, et al. Among authors: yakovich a. Oncoimmunology. 2020 Nov 19;9(1):1847846. doi: 10.1080/2162402X.2020.1847846. Oncoimmunology. 2020. PMID: 33312760 Free PMC article. Clinical Trial.
Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
George TG, Endeshaw MM, Morgan RE, Mahasenan KV, Delfín DA, Mukherjee MS, Yakovich AJ, Fotie J, Li C, Werbovetz KA. George TG, et al. Among authors: yakovich aj. Bioorg Med Chem. 2007 Sep 15;15(18):6071-9. doi: 10.1016/j.bmc.2007.06.042. Epub 2007 Jun 27. Bioorg Med Chem. 2007. PMID: 17618122 Free PMC article.
Inhibitors of tubulin assembly identified through screening a compound library.
Morgan RE, Ahn S, Nzimiro S, Fotie J, Phelps MA, Cotrill J, Yakovich AJ, Sackett DL, Dalton JT, Werbovetz KA. Morgan RE, et al. Among authors: yakovich aj. Chem Biol Drug Des. 2008 Dec;72(6):513-24. doi: 10.1111/j.1747-0285.2008.00729.x. Chem Biol Drug Des. 2008. PMID: 19090918 Free PMC article.
13 results